Pulmonary hypertension can be fatal, but it is not an immediate death sentence. Across all types, about 85% of patients survive at least one year, 64% survive three years, and 51% survive five years, based on data from a large international registry of over 8,500 patients. Those numbers vary widely depending on the type of pulmonary hypertension, how early it’s caught, and how well it responds to treatment. Some patients live decades with the condition; others decline rapidly within a few years.
How Pulmonary Hypertension Becomes Life-Threatening
Pulmonary hypertension kills primarily by destroying the right side of the heart. The right ventricle is built to pump blood into the lungs at low pressure. When the blood vessels in the lungs stiffen or narrow, that pressure climbs, and the right ventricle has to work much harder than it was designed to.
At first, the heart muscle compensates. It contracts more forcefully and begins to thicken, similar to how a bicep grows when you lift heavier weights. For a while, this keeps blood flowing normally. But unlike a bicep, the right ventricle can’t sustain that extra workload indefinitely. The muscle wall stretches and dilates, the chamber becomes more spherical, and the valve between the right ventricle and its upper chamber stops closing properly. Blood starts leaking backward with every heartbeat, creating a vicious cycle of worsening overload, declining pumping ability, and falling cardiac output. In advanced stages, the heart simply can’t push enough blood forward to supply the body, which is why fainting and sudden collapse can occur. Right heart failure is the most common cause of death in pulmonary hypertension.
Survival Without Treatment vs. With Treatment
Before effective medications existed, the outlook was grim. Untreated pulmonary arterial hypertension (the form that originates in the lung arteries themselves) carried a median survival of just 2.8 years. Only 68% of untreated patients survived one year, 48% survived three years, and 34% made it to five years.
Modern therapies have substantially changed those numbers. In one landmark study published in Circulation, patients treated with a continuous infusion medication had survival rates of 88% at one year, 76% at two years, and 63% at three years, nearly double the expected survival based on historical data. Newer oral medications that relax the lung blood vessels or block the pathways that cause them to thicken have continued to improve outcomes. A European registry tracking patients with idiopathic and hereditary forms found one-year survival of 91% to 92%, five-year survival of 65% to 66%, far exceeding what older prediction models anticipated.
Why the Type of Pulmonary Hypertension Matters
Pulmonary hypertension is classified into groups based on its underlying cause, and the group you fall into heavily influences your prognosis.
- Group 1 (pulmonary arterial hypertension): This includes cases where the lung arteries themselves are the primary problem, whether from genetic factors, autoimmune diseases, or unknown causes. It’s the most studied form and the one with the most targeted drug therapies. Five-year survival with modern treatment ranges from roughly 61% to 66%, depending on the specific subtype.
- Group 2 (left heart disease): The most common cause of pulmonary hypertension overall. High pressure backs up from the left side of the heart into the lungs. Outcomes depend largely on managing the underlying heart condition. In children, this group carries the worst prognosis of any category.
- Group 3 (lung disease): Conditions like COPD or pulmonary fibrosis damage the lung tissue and raise pulmonary pressure. Treating the lung disease is the primary strategy, since the medications designed for Group 1 often don’t help here.
- Group 4 (chronic blood clots): Known as CTEPH, this form results from old blood clots that never fully dissolved in the lung arteries. It has the most dramatic treatment divide of any group (more on this below).
CTEPH: The Most Treatable Form
Chronic thromboembolic pulmonary hypertension stands apart because it can sometimes be cured, or nearly so, with a surgical procedure that physically removes the scar tissue and old clot material from the lung arteries. A worldwide registry tracking outcomes found that patients who underwent this surgery had a three-year survival rate of 94%. A newer, less invasive procedure using balloon catheters achieved 92% at three years. Patients who received only medications and no procedure of either type had a three-year survival of just 71%, with 27% dying during the follow-up period compared to 7% of surgical patients. The gap is striking and makes CTEPH one of the most important forms to diagnose correctly, since the right intervention can be transformative.
Outcomes in Children
Pulmonary hypertension in children is rare but carries its own set of challenges. A 20-year national study following nearly 1,000 children found transplant-free survival of 87% at one year, 74% at five years, and 69% at ten years. About 24% of children in the study died during follow-up, and another 3.5% required a lung or heart-lung transplant.
The underlying cause makes a significant difference in pediatric outcomes. Children whose pulmonary hypertension was related to congenital heart defects had the best survival, while those with pulmonary hypertension from left heart disease fared the worst. The fact that nearly 70% of children survived a full decade reflects how much aggressive, early treatment can accomplish in younger patients whose hearts still have some capacity to adapt.
What Affects Individual Prognosis
Population-level survival statistics only tell part of the story. Several factors tilt the odds for any individual patient. How well the right ventricle is functioning at diagnosis is one of the strongest predictors. Patients diagnosed early, before the heart has started to dilate and fail, consistently do better than those diagnosed late. Exercise capacity matters too: people who can walk farther and maintain physical activity tend to have longer survival.
Response to treatment is another key variable. Patients whose lung pressures drop and whose heart function stabilizes on medication can sometimes maintain a relatively normal life for many years. Those who don’t respond, or who continue to worsen despite treatment, face a shorter timeline. For patients with progressive disease who are otherwise good candidates, lung transplantation remains an option. Post-transplant outcomes for pulmonary hypertension patients show roughly 82% to 85% surviving one year and about 59% to 62% surviving five years, though the presence of elevated lung pressures does reduce transplant survival compared to patients transplanted for other reasons.
The trajectory of pulmonary hypertension has shifted meaningfully over the past two decades. A disease that once carried a near-certain death sentence within a few years now allows many patients to live well beyond five or ten years with appropriate treatment, and for some forms like CTEPH, near-normal life expectancy is achievable.